Insider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) Director Sells 3,900 Shares of Stock

2seventy bio, Inc. (NASDAQ:TSVT) Director Marcela V. Maus sold 3,900 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $3.38, for a total value of $13,182.00. Following the sale, the director now directly owns 23,752 shares of the company’s stock, valued at $80,281.76. This represents a 14.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

2seventy bio Stock Performance

Shares of 2seventy bio stock opened at $3.61 on Friday. 2seventy bio, Inc. has a one year low of $1.67 and a one year high of $6.40. The stock’s 50-day moving average is $4.61 and its 200-day moving average is $4.45.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lowered their price target on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $9.00.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SkyView Investment Advisors LLC grew its stake in shares of 2seventy bio by 25.0% in the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after buying an additional 2,500 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in 2seventy bio by 11.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company’s stock valued at $155,000 after acquiring an additional 2,893 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of 2seventy bio in the 3rd quarter valued at about $25,000. XTX Topco Ltd increased its stake in shares of 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after purchasing an additional 9,257 shares during the last quarter. Finally, BBR Partners LLC raised its holdings in shares of 2seventy bio by 66.7% in the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock valued at $96,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.